Lisocabtagene-maraleucel: Cytokine release syndrome.

A study reported a case of cytokine release syndrome (CRS) in a patient with refractory diffuse large B-cell lymphoma (DLBCL) who was treated with lisocabtagene-maraleucel. The patient experienced grade 3 CRS, but the duration of treatment and outcome were not specified. The study included a total of 20 patients treated between September 2021 and March 2022, but no further details about these patients were provided. [Extracted from the article]